drug

tafasitamab

1 story · latest Jul 28, 2026

Status: Investigational
Codes: INCMOR00208, MOR00208
Trials: 1 registered trial in coverage

Relationships

Developed by Incyte Corporation

Timeline

Trial registered for tafasitamab plus rituximab in newly diagnosed follicular lymphoma

Jul 28Trial updateIncyte Corporation rituximab

Biotech intelligence from primary sources. Every story is an original summary of a public record, linked to its source. Not investment advice.

Terms Privacy hello@readthrough.news

readthrough is a product of JAMN Ventures, LLC.